Rocket Lab Is Up Nearly 250% in a Year. Is This the 1 Space Stock You Buy on Every Dip and Never Sell?

Rocket Lab posted record 2025 revenue of $602 million, up 38% year over year, while backlog surged 73% to nearly $1.9 billion. The company also flew 21 missions last year with a 100% success rate and won an $816 million Space Development Agency contract, but it remains unprofitable with roughly $200 million in losses and trades at about 66x sales. The upcoming Neutron rocket is the key catalyst, with potential to challenge SpaceX's Falcon 9, though execution and launch delays remain major risks.

Analysis

RKLB is transitioning from a “story stock” to a capital intensity and execution stock. The market is now valuing the company as if Neutron arrives on time, scales reliably, and meaningfully closes the unit economics gap versus incumbents; that creates a fragile setup because any schedule slip tends to compress multiple expansion faster than fundamentals can catch up. The bigger second-order issue is that backlog quality matters more than backlog size: defense and government contracts de-risk demand, but they do not eliminate launch cadence, margin, and working-capital risk.

The competitive dynamic is asymmetric. If Neutron works, RKLB can win share not just from launch providers but from smaller satellite integrators and constellation operators that prefer single-vendor execution and tighter mission control. If it misses, the company could get trapped in a “good hardware, bad economics” regime where commercial customers use it as a bargaining chip against SpaceX and ULA while waiting for better pricing elsewhere. The real winner under a successful Neutron rollout may be upstream suppliers of avionics, propulsion components, and defense electronics, because volume inflection would pull through a broader ecosystem before RKLB itself achieves durable earnings power.

The market is underestimating how binary the next 12-18 months are. This is not a multi-quarter fundamentals grind; it is a milestone-driven re-rating process around test cadence, launch reliability, and customer conversion. A clean technical and first-commercial sequence could justify another leg higher, but a delay or anomaly likely produces a 25-40% air pocket as premium valuation stocks lose multiple support quickly.

Consensus is missing that the current valuation already discounts “competent execution,” not just success. The upside from here is less about revenue growth and more about proving RKLB can convert backlog into free cash flow without persistent dilution or launch-related surprises. That makes this attractive only if you are willing to own a high-beta optionality vehicle with event risk, rather than a durable compounder today.

Key Decisions for Investors

• Maintain a tactical long only into confirmed Neutron milestones; use a 6-12 month horizon and size small because the stock is pricing in successful execution already.
• Buy RKLB Jan-2027 out-of-the-money calls instead of common for upside exposure; this captures a potential re-rating if Neutron de-risks while capping downside to premium paid.
• Fade strength via call spreads after sharp rallies: sell RKLB upside against near-term catalysts if the stock expands further before launch proof, since multiple compression risk is asymmetric on delays.
• Pair trade: long RKLB / short a basket of mature aerospace-defense primes only if Neutron progress is independently verified; otherwise prefer the reverse trade because maturity stocks carry less binary risk.
• Set a hard stop on any long exposure around the first meaningful Neutron slip or anomaly; the risk/reward flips quickly from optionality to value trap if schedule credibility breaks.